Wataru Okamoto

3.5k total citations
97 papers, 1.8k citations indexed

About

Wataru Okamoto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Wataru Okamoto has authored 97 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 32 papers in Cancer Research. Recurrent topics in Wataru Okamoto's work include Colorectal Cancer Treatments and Studies (50 papers), Cancer Genomics and Diagnostics (30 papers) and Gastric Cancer Management and Outcomes (21 papers). Wataru Okamoto is often cited by papers focused on Colorectal Cancer Treatments and Studies (50 papers), Cancer Genomics and Diagnostics (30 papers) and Gastric Cancer Management and Outcomes (21 papers). Wataru Okamoto collaborates with scholars based in Japan, United States and Italy. Wataru Okamoto's co-authors include Kazuhiko Nakagawa, Kazuto Nishio, Isamu Okamoto, Takayuki Yoshino, Kiyoko Kuwata, Haruka Yamaguchi, Tokuzo Arao, Atsushi Ohtsu, Ken Takezawa and Yasutoshi Kuboki and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Wataru Okamoto

88 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wataru Okamoto Japan	23	1.2k	777	555	402	375	97	1.8k
David J. Mauro United States	11	1.6k 1.4×	755 1.0×	459 0.8×	451 1.1×	376 1.0×	26	2.0k
Elisa Sensi Italy	20	1.5k 1.3×	586 0.8×	609 1.1×	555 1.4×	396 1.1×	44	2.3k
Jean‐Luc Canon Belgium	11	1.6k 1.3×	691 0.9×	314 0.6×	389 1.0×	312 0.8×	12	1.8k
Cristiana Lupi Italy	18	1.7k 1.4×	631 0.8×	708 1.3×	608 1.5×	370 1.0×	35	2.8k
Guillem Argilés Spain	24	1.8k 1.5×	602 0.8×	719 1.3×	621 1.5×	422 1.1×	95	2.5k
Ilona Kocáková Czechia	10	1.6k 1.4×	695 0.9×	282 0.5×	404 1.0×	336 0.9×	33	1.9k
M. Elisa Vink-Börger Netherlands	9	1.3k 1.1×	535 0.7×	291 0.5×	487 1.2×	340 0.9×	9	1.6k
Vinod Ganju Australia	24	2.0k 1.7×	906 1.2×	655 1.2×	316 0.8×	447 1.2×	94	2.7k
Claudia Maggi Italy	21	873 0.7×	360 0.5×	261 0.5×	332 0.8×	301 0.8×	36	1.3k

Countries citing papers authored by Wataru Okamoto

Since Specialization

Citations

This map shows the geographic impact of Wataru Okamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wataru Okamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wataru Okamoto more than expected).

Fields of papers citing papers by Wataru Okamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wataru Okamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wataru Okamoto. The network helps show where Wataru Okamoto may publish in the future.

Co-authorship network of co-authors of Wataru Okamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Wataru Okamoto. A scholar is included among the top collaborators of Wataru Okamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wataru Okamoto. Wataru Okamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Imai, Mitsuho, Yoshiaki Nakamura, Sangwon Shin, et al.. (2025). Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial. JCO Precision Oncology. 9(9). e2400385–e2400385. 2 indexed citations

Ohba, Akihiro, Chigusa Morizane, Yasuyuki Kawamoto, et al.. (2024). Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. Journal of Clinical Oncology. 42(27). 3207–3217. 20 indexed citations

Namba, Masashi, et al.. (2023). Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer. Internal Medicine. 62(20). 3001–3004. 4 indexed citations

Ishii, Yasutaka, Masahiro Serikawa, Wataru Okamoto, et al.. (2023). A case of unresectable intrahepatic cholangiocarcinoma with a germline BRCA1 mutation. Clinical Journal of Gastroenterology. 16(3). 470–475.

Sakamoto, Yasutoshi, Hideaki Bando, Yoshiaki Nakamura, et al.. (2022). Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world Data. Clinical Colorectal Cancer. 22(1). 45–52. 11 indexed citations

Fujii, Yasutoshi, Atsushi Ono, C. Nelson Hayes, et al.. (2021). Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. Journal of Experimental & Clinical Cancer Research. 40(1). 215–215. 32 indexed citations

Hatanaka, Yutaka, Takeshi Kuwata, Eiichi Morii, et al.. (2021). The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine. Pathology International. 71(11). 725–740. 38 indexed citations

Kuwata, Takeshi, Masashi Wakabayashi, Yutaka Hatanaka, et al.. (2020). Impact of DNA integrity on the success rate of tissue‐based next‐generation sequencing: Lessons from nationwide cancer genome screening project SCRUM‐Japan GI‐SCREEN. Pathology International. 70(12). 932–942. 22 indexed citations

Yoshikawa, Yuki, Michio Imamura, Yumi Kosaka, et al.. (2020). A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. Clinical Journal of Gastroenterology. 14(1). 283–287. 21 indexed citations

10.

Sawada, Kentaro, Yoshiaki Nakamura, Takeharu Yamanaka, et al.. (2018). Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 17(3). 198–205. 62 indexed citations

11.

Okamoto, Wataru, Hideaki Bando, Takafumi Fukui, et al.. (2017). Clinical utility of quasi-monomorphic variation range (QMVR) on the determination of microsatellite instability (MSI) status in patients (pts) with colorectal cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01. Annals of Oncology. 28. v192–v193.

12.

Okamoto, Wataru & Takayuki Yoshino. (2016). Integration of clinical information and molecular biology profile -Endeavor of SCRUM-Japan-.. PubMed. 74(11). 1812–1817. 1 indexed citations

13.

Kurata, Takayasu, Junji Tsurutani, Yasuhito Fujisaka, et al.. (2014). Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer. Investigational New Drugs. 32(5). 946–954. 9 indexed citations

14.

Okamoto, Wataru, Isamu Okamoto, Tokuzo Arao, et al.. (2012). Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification. Molecular Cancer Therapeutics. 11(7). 1557–1564. 73 indexed citations

15.

Hayashi, Hidetoshi, Junji Tsurutani, Norikazu Masuda, et al.. (2011). Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B. Breast Cancer. 20(2). 131–136. 14 indexed citations

16.

Okamoto, Wataru, Isamu Okamoto, Tokuzo Arao, et al.. (2011). Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. British Journal of Cancer. 105(3). 407–412. 25 indexed citations

17.

Okamoto, Wataru, Isamu Okamoto, Takeshi Yoshida, et al.. (2010). Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition. Molecular Cancer Therapeutics. 9(5). 1188–1197. 58 indexed citations

18.

Okamoto, Kunio, Isamu Okamoto, Wataru Okamoto, et al.. (2010). Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for EGFR Mutations. Cancer Research. 70(24). 10402–10410. 75 indexed citations

19.

Okamoto, Isamu, Hiroyasu Kaneda, Taroh Satoh, et al.. (2010). Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 9(10). 2825–2833. 79 indexed citations

20.

Yoshida, Takeshi, Isamu Okamoto, Wataru Okamoto, et al.. (2009). Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplification. Cancer Science. 101(1). 167–172. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact